ANI Pharmaceuticals, Inc. reported $978M of revenue over the trailing twelve months, +31% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $978M (to Q2 2026). Net income: $108M, trailing twelve months to Q2 2026. Free cash flow: $173M, trailing twelve months to Q2 2026. Operating margin: 15%, trailing twelve months to Q2 2026.

ANIPANI Pharmaceuticals, Inc.

Healthcare

$73.92-24% 1Y

$73.92

$70.1652 weeks$95.93

ANIP as reported

ANI Pharmaceuticals, Inc. reported $978M of revenue over the trailing twelve months, +31% on the year before. 11 reported series are charted on this page, each one as filed.

$978M

Revenue, trailing twelve months · to Q2 2026 · +31% against the twelve months before

Net income: $108M
Net income · −1161% year on year · trailing twelve months to Q2 2026
Free cash flow: $173M
Free cash flow · +38% year on year · trailing twelve months to Q2 2026
Operating margin: 15%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ANIP, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$978M	+31%	Q2 2026
Net income	$108M	−1161%	Q2 2026
EPS	$4.63	−701%	Q2 2026
Gross margin	60%	n/a	Q2 2026
Operating margin	15%	n/a	Q2 2026
Net margin	11%	n/a	Q2 2026
ROE	14%	n/a	Q2 2026
ROA	5.5%	n/a	Q2 2026
ROIC	16%	n/a	Q2 2026
Free cash flow	$173M	+38%	Q2 2026
P/E	16.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.